IPSC Stock Analysis: Buy, Sell, or Hold?
IPSC - Century Therapeutics, Inc. Common Stock
$2.07
0.05 (2.48%)
▲
5d:
+7.81%
30d:
-4.61%
90d:
-8.81%
BUY
HIGH Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When IPSC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: IPSC shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: IPSC shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: IPSC is currently trading at $2.07, which is considered fair relative to its 30-day fair value range of $1.96 to $2.17.
Technical Outlook: Technically, IPSC is in a downtrend. The price is approaching resistance at $2.12. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IPSC scores 74/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $4.75 (+129.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IPSC is in a downtrend. The price is approaching resistance at $2.12. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IPSC scores 74/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $4.75 (+129.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.96 -
$2.17
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (74/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 129.5% below Wall St target ($4.75)
- BULLISH: Bottoming setup score 74/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$1.96 -
$2.17
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.19
(9.3%)
Support & Resistance Levels
Support Level
$1.89
Resistance Level
$2.12
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.57
Wall Street Target
$4.75
(+129.5%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 23, 2026 9:57 AM ET
Data refreshes hourly during market hours. Next update: 10:57 AM
Data refreshes hourly during market hours. Next update: 10:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IPSC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Gregory Russotti
SELL
10076 shares
2026-03-12
Douglas Carr
SELL
7043 shares
2026-03-12
Gregory Russotti
SELL
479 shares
2026-03-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1173 | 43 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 39 SELL |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 26 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 55 HOLD |
